Kristeen Maniscalco

GlaxoSmithKline (United Kingdom) — United Kingdom

Medicine · Health Sciences

7h-index401citations11works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cardiovascular Disease and Adiposity(3), Apelin-related biomedical research(3), Cardiovascular, Neuropeptides, and Oxidative Stress Research(3), Nitric Oxide and Endothelin Effects(2), Renin-Angiotensin System Studies(2)

Publications11 total

Comparison of Soluble Guanylate Cyclase Stimulators and Activators in Models of Cardiovascular Disease Associated with Oxidative Stress
Frontiers in Pharmacology·2012· 59 citedOpen Access
Abstract 13510: Discovery of Orally Active Transient Receptor Potential Vanilloid 4 (TRPV4) Blockers for the Treatment of Pulmonary Edema in Heart Failure
Circulation·2011· 1 cited
Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease
Journal of Pharmacology and Experimental Therapeutics·2009· 50 cited
Chronic inhibition of 11beta‐hydroxysteroid dehydrogenase activity reduces cardiovascular comorbidities in corpulent and stroke‐prone SHR
The FASEB Journal·2008
Abstract 1289: Activation of the Transient Receptor Potential V4 Channel Causes Cardiovascular Collapse Mediated by Endothelial Failure
Circulation·2007
PPARδ Activation Normalizes Cardiac Substrate Metabolism and Reduces Right Ventricular Hypertrophy in Congestive Heart Failure
Journal of Cardiovascular Pharmacology·2007· 40 cited
Quantitative <SMALL>A</SMALL>nalysis of <SMALL>O</SMALL>rphan G <SMALL>P</SMALL>rotein-<SMALL>C</SMALL>oupled <SMALL>R</SMALL>eceptor mRNAs by TaqMan<SUP>®</SUP> <SMALL>R</SMALL>eal-<SMALL>T</SMALL>ime PCR: G2A and GPR4 <SMALL>L</SMALL>ysophospholipid <SMALL>R</SMALL>eceptor <SMALL>E</SMALL>xpression in <SMALL>L</SMALL>eukocytes and in a <SMALL>R</SMALL>at <SMALL>M</SMALL>yocardial <SMALL>I</SMALL>nfarction-<SMALL>H</SMALL>eart <SMALL>F</SMALL>ailure <SMALL>M</SMALL>odel
Humana Press eBooks·2005
Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection
Cardiovascular Research·2005· 42 citedOpen Access
Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators
Naunyn-Schmiedeberg s Archives of Pharmacology·2004· 102 cited
Urotensin-II: a novel systemic hypertensive factor in the cat
Naunyn-Schmiedeberg s Archives of Pharmacology·2004· 42 cited
Deletion of the UT receptor gene results in the selective loss of urotensin‐II contractile activity in aortae isolated from UT receptor knockout mice
British Journal of Pharmacology·2003· 65 citedOpen Access

Frequent Co-authors

Robert N. Willette(9), David J. Behm(6), Alan R. Olzinski(5), Douglas G. Johns(4), Stephen A. Douglas(4), Melissa H. Costell(4), Christine G. Schnackenberg(4), Zhaohui Ao(3), Lea Sarov‐Blat(3), Klaudia Steplewski(3), Robert W. Coatney(3), Christopher Doe(3), Beat M. Jucker(3), Marianne Eybye(3), Chris P. Doe(3), Nambi Aiyar(2), John J. Lepore(2), Ross Bentley(2), Gerald P. Stankus(2), R Bentley(2)